Drug profile · INN
timolol maleate
TIMOPTIC IN OCUDOSE
timolol maleate (TIMOPTIC IN OCUDOSE) is a beta-1 adrenergic receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — timolol maleate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
timolol maleate (TIMOPTIC IN OCUDOSE) is a beta-1 adrenergic receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is timolol maleate?
timolol maleate (TIMOPTIC IN OCUDOSE) is a beta-1 adrenergic receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for timolol maleate?
TIMOPTIC IN OCUDOSE is a marketed brand name for timolol maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of timolol maleate?
timolol maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.